🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

REVIEW Nature Immunology Caitlin Zebley, MD PhD T cell dysfunction and therapeutic intervention in cancer nature.com/articles/s4159…

Our new #paper is out in Nature Immunology. Applying #spatial transcriptomics at subcellular resolution to 130 ovarian #cancer tumors, followed by data-driven experimental design and high content #CRISPR screens to map immune evasion in ovarian cancer nature.com/articles/s4159… (1/15)

🟢NEW REVIEW NatureRevClinOncol where EleonoraGhisoni Matteo Morotti George Coukos & al. propose the implementation of systematic CD8+ T immunophenotypic classification to personalize #immunotherapy combinations in #OvarianCancer Ludwig Cancer 📎rb.gy/9otjq1

We’re excited to announce a two-day #LabLinks on Tumor immunotherapy and immunology, organized by scientists Ludwig Cancer & Cell Press editors. This event is free to attend but places are limited. Register: hubs.li/Q02NRvsP0

#NEWS: CDR-Life hits major milestones in cancer immunotherapy! ✅ First patient dosed with CDR404 (MAGE-A4 target) ✅ CDR813 (PRAME target) advances as promising clinical candidate Our M-gager® tech is pushing boundaries in solid tumor treatment. lnkd.in/e2VQrW4X

Tumor-reactive T cell clonotype dynamics underlying clinical response to TIL therapy in melanoma Immunity George Coukos cell.com/immunity/fullt…

A vaccine to prevent ovarian cancer? 🧬 It’s in the works at Oxford and patients are helping shape it. Read how our Research Network volunteers played a key role in designing this life-saving project. pulse.ly/gqc8xdjw4s #OvarianCancerPrevention #PatientInvolvement

Thrilled to share our recent work out today in nature on an mRNA therapeutic to treat pre-eclampsia! This work has been a true passion project from my time Penn Bioengineering in Mike Mitchell, and I’m excited to continue important research in women’s health! nature.com/articles/s4158…

#GI25 ASCO 🌟 Practice-changing ALASCCA ph3 trial 🇸🇪 📌 ASA 160mg in PIK3CA+ stage II-III #CRCsm 📌 PIK3CA+ in 37% ➡️ HR 0.42 for 3yr DFS! OncoAlert

Novel strategies to manage CAR-T cell toxicity tinyurl.com/ye3c94na This new Review discusses management of safety issues for CAR-T cell therapies such as cytokine release syndrome, as well as druggable targets and cellular engineering strategies to develop safer CAR-T cells

CIDER now works with Seurat v5! 🎉 CIDER helps evaluate scRNA-seq integration, and we’ve updated it for the latest version. Try it out: zhiyuan-hu-lab.github.io/CIDER/. Let us know if you have any questions! 🚀

The ESGO Council is extremely saddened to learn of the untimely death of Prof Giovanni Scambia, who was a great influence to and personal friend of many of our members. A moment of silence was held today during the Congress opening ceremony in his honour. Prof Scambia touched

📊 Who’s on the podium at #ASCO? Audit of 1563 oral presentations (2021–24) reveals: 🇺🇸 USA – 66.7% 🇨🇳 China – 6.3% 🇫🇷 France – 4.0% 🇬🇧 UK – 3.2% 🇨🇦 Canada – 2.3% 🇯🇵 Japan – 1.8% 🇩🇪 Germany – 1.4% 🇰🇷 South Korea – 0.8% 🌍 Africa – 0% 🌎 South America – 0.3% 🌏 Middle East – 0.1%

#foodforthought 🍔🍕🍪🤔: the impact of infusion time of #ICIs is huge! ⏰ How many of our #immune checkpoint inhibitor clinical trials which #failed in the randomised setting may have done so ‘cos there was no stratification for this? #ASCO25 #CircadianRhythm Jordi Remon

Review Nature Rev Immunol George Coukos Tumor-associated vasculature in T cell homing and immunity: opportunities for cancer therapy nature.com/articles/s4157…

We, the Weizmann Institute of Science community, deeply mourn the passing of Prof. Zelig Eshhar of the Department of Immunology and Regenerative Biology. Prof. Eshhar was a trailblazing scientist in the field of cancer immunotherapy, a recipient of the Israel Prize in Life